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Current Practice Regarding the Use of Fatty Livers:
A Trans-Atlantic Survey
ChurlesJ. Imber, Shuwn D. St. Peter, Inigo Lopez, Lynden Guiver, una?
PeterJ. Friend
A strong association exists between the presence of steatosis in a donor liver for transplantation and thedevelopment of primary nonfunction in the recipient. Despite
this, appraisal of
the donorremains one of the least scientific aspects of
the transplantationprocess, and many centers base their practice on subjective opinion, rather than
objective data. We conducted this survey to illuminate
controversial issuesand highlight the variation ofopinion
and practice policiesboth between and within the United
Kingdom and the United States. A simple, anonymous,
one-page, 10-question survey with tick-box answerswas
sent to every practicing liver transplant surgeon in the
United Kingdom. The same form was sent by E-mail to
liver transplant surgeons in the United States witha current E-mailaddresslisted in the AmericanSocietyof
Transplant Surgeons registry.In the United Kingdom, 16
of 19 surgeons polled responded (84.2%) and thus were
considered representative. From the United States, there
were 78 respondents from 52 centers, representingall l1
United Network for Organ Sharing regions. We found
that current practicepoliciesdiffer
not onlybetween
nations, but also among centersin each country. US surgeons generally follow
a more conservative approach, with
greateremphasis on histologicalassessment. Dichotomous opinions exist on thesignificance of microvesicular
steatosis in bothcountries. Most evident from
this survey
is that more researchin thefield is required
to help answer
thesequestions and allowfor the safeuseofallviable
livers. (Liver Tramp1 2002;8:545-549.)
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ture. The situation is confused furtherby differing practices among institutions based on personnel experience
and highly subjective opinion.
If meaningful audit of best practice is to be established with theaim ofimproving standards,it is imperative that an accurate impressionof current clinical
practice within the international transplant community
be established. This survey was designed for this purpose and also to identify differences between United
States (US) and United Kingdom (UK) practice.

Methods
A simple,anonymous,10-questionsurveywithtick-box
answers was sentto every practicing liver transplant surgeon
in the United Kingdom. An identical proforma was sent by
E-mail to every liver transplant surgeon with a current E-mail
of Transplant Surgeons
address listed in the American Society
registry in the United States. These results have been categorically compiled.

Results
In the UK, 16
of the 19 practicing liver transplant
surgeons responded (84.2%); therefore, this was consideredrepresentative. Fromthe US, there were 78
respondents from52 centers, representing all 11 United
Network for Organ Sharing (UNOS) regions. Using
data from theUNOS Web site based on 1999statistics,
these centers accountedfor 82.6% of liver transplantations performed that year. Results are shown in Figure
1, with percentages of respondents listed for both UK
and US data.

ne of the least scientific aspects of
the liver transp 1a n tation process is appraisal of the donor liver.
This is particularly truewith regard to steatosis, in
which preretrieval liver function test results are seldom
elevated to a clinically significant level, and the subjective opinion of the surgeon determines the fate of the
organ. The fear oftransplanting afatty liver is basedon
the strongassociation with primary nonfunction(PNF)
after a periodof coldpreservation, initially described by
Todo et a l l from the University of Pittsburgh. However, ifa valid and standard method
of assessmentcould
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Figure 1. Comparison of UK and US responses to Fatty Liver Survey.

Discussion

the ing
prevalence of fatty change from
in livers
braindead adult and pediatric donors. Thisranges from 13%
The II-IOS~
answer concerningthe Prevalence
to 26% in cases in which
biopsy
specimens
are
stained
of steatosis, with 44% of UK and 49% of US responwith hematoxylin and eosin (H&E).2 This large disdents, estimated the percentage of steatotic livers
crepancy among centers maybecausedby genuine variretrieved in their region to be between 20% and 40% of ations
bemeen donor pools, as well as variable &fin;the total. A wide disparity exists in the literature regardtions of fatty change.

The Use of Fatty Liversfor Transplantation: A Survg

The use of fat-specific staining has been shown to
identify greater levels of steatosisthan seen byH8~E.3-5
Markin et al,4 using Oil red 0,found steatosis in 5 1%
of 187 livers. The investigators dismissed this figure by
stating that Oil red 0 is unreliable for fatty change in
the liver because it stains sinusoids, as well as vacuoles.
Another series of 83 consecutive donor wedge biopsies
showed greater than 30% steatosis in 49% of sections
stained with toluidineblue.5
The most commonlyused means of
predicting function of a liver after transplantation is surgical assessment
by the retrieval surgeon. Thisis based on the combination of appearance andtexture, but is inevitably subjective. This is the only methodof liver appraisalcurrently
applied by 50% of UK respondents whonever incorporate histopathologic assessment into their decisionmaking process. This is in direct contrast to the United
States, where 100% of transplant surgeons useliver
biopsy under some circumstances. Although the reasoningbehind this dissimilarity maybecausedby
greater awareness of the threat of litigation within the
United States, it would appear fromobjective scientific
data to be the correct one.
Attempts at practical assessment of the degree of
steatosis havenot proved reliable. In oneseries, 66% of
steatotic liverswere described as normalonmacroscopic appearance by a surgeon, with predictivevalues
of 71%, 46%, and 17% for massive, moderate, and
mild change, respectively.6 In another study, 38% of
livers judged to be normal macroscopically showedfatty
change on histopathologic appraisal.3 Certainly, severe
steatosis can be identified by yellow discoloration after
flushing, rounded edges, anda greasyfirm texture.
However, this is obviously a highly subjective test that
becomes less sensitive with lesser degrees of steatosis.
Three quarters of US respondents perform abiopsy
whenanorgan
appearsmacroscopically steatotic or
such adverse donor risk factors as age and body mass
index prejudice the
use ofthe organ. Forty-four percent
of UK surgeons perform biopsy
a
ifmacroscopic change
exists,whereas only 6% performaprotocol
biopsy
regardless ofother factors. Both groupstake one ortwo
specimens, predominantlyon thebackbench in the UK
and at the time
of retrievalin theUS. They also differin
relation to the position of their biopsy sampling; US
teams predominantly
obtain
random
samples as
opposed to sampling thesame position in the UK.The
area of greatest macroscopic changeis chosen for biopsy
less commonly in both countries (19%, U K 6%, US).
Fatty infiltration of the liver has beenshown to have
a nonuniform distributionby radiological assessment.7
It therefore appears intuitive that one or two biopsy
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specimens from an entire liver may provide inaccurate
and misleading information. Variationof biopsy interpretation between pathologists atdifferent centers also
is a confounding factor. Chinnakotla et a18 recently
reported thesuccessful transplantation of liversdeemed
severely steatotic at other centers, but acceptableby
their own pathologist. However, at present, this appears
to be the only widely available and logistically acceptable technique that offers an objective method of quantifyingsteatosis and a framework on which to base
decisions. It is suggested in the literature that protocol
biopsies performed regardless ofother donorfactors can
improve outcome. This was exemplified by Markin et
al,* who reported a reductionin PNF rates from 8.4%
to 1.4% after instituting a policy ofprotocol biopsy and
discarding livers with greater than 45% steatosis.
We attempted to determine what severity of macrovesicular change was considered an absolute contraindication for acceptance ofa donorliver when biopsies
had been performed. In both groups
of respondents, the
acceptablerangeofsteatosisvariedwidely
(Fig. 2).
US respondentstendedtowardamore
conservative
approach, with alarger proportion of surgeons acceptingonly livers with less than 50% macrovesicular
change. Conversely, 43% of UK surgeons would accept
up to 60% change.
Fifty percent of respondents in the UK do not perform abiopsy at all, which explains the high proportion
ofthesesurgeons
notresponding to this question
(20%), as well as 19% who reported no upperlimit on
histological grounds.
Ploeg et al9 originally suggested a classification of
fatty change as mild (<30% of visualized hepatocytes
involved),
moderate
(30% to 6O%), and severe
(>6O%), a system approximately appliedby most centers. In the early 1990s, fourstudies examined the relationship of fatty change to PNF.2,4,6,9 Thelargest of
these assessed 390 frozen section biopsy specimens and
found that 13% of grafts showing greater than 30%
steatosis showedPNF compared with2.5% of nonsteatotic grafts.6 Progressive deterioration in graft survival
was observed from mildto massive steatosis;thus, it was
concluded that grafts with severe steatosis should be
discarded, and those with moderate change should be
evaluated in conjunction with othercriteria, such as the
condition of the recipient and availability of organs at
that time. The institution involved, in line with most
others worldwide, found no contraindicationto transplanting livers with minimalchange. This concurs with
the findings of Ploeg et al,9 who found PNF rates as
high as 80% in severely steatotic organs, but more wor-
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Figure 2. Maximum percentage of steatosisconsidered
UK and US
acceptableby
respondents
before
acceptance of a donor liver.
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ryingly, initial poor function rates as high as 30% in
moderately steatotic livers.
These studies suggest that mildto moderate steatosis
is not a contraindication for transplantation, but merely
a risk factor for eventual graft loss. This was not borne
out in ourstudy because 50% and 68% of UK and US
respondents stated they would consider greater degrees
of steatosis in urgent or superurgent recipients, who by
definition are the sickest. Although this would appear
from published data to be a dangerous practice, no
study to our knowledge has specifically examined this
controversy.
No published data address the correlation between
number or position of biopsies and their accuracy in
assessing steatosis. Liver density assessed by computed
tomography (CT) accurately reflects the presence of
steatosis throughout the liver, and techniques to convert Hounsfield units into
real fat volume fractions have
been developed.
Given that hepatic steatosis is not
homogeneous and macroscopic estimation by the
retrieval surgeon is not accurate, it wouldseem intuitive
that a more accurate estimation ofsteatosis throughout
the entire organpotentially could be achieved byradiological assessment of each donor. However, although a
positive finding on CT or magnetic resonance imaging
(MRI) has correlated positively with steatosis on
biopsy, the converse recently was not shown to be the
case, with 30% of negative scans on MRI and24% of
those on CT associated with greater than 10% steatosis. l 2
Given these recent data, together with logistic difficulties and cost of performing CT or MRI on potential

donors, it is not surprising that so few respondents are
currently using radiologicalassessment
to evaluate
potential cadaveric donor livers. Considering the catastrophic outcome ofPNF andenormous consumption
of resources associated with urgent retransplantation,
radiological assessment possibly could be considered in
the future if diagnostic sensitivity could be improved.
More studies investigating the application of available
technology to the evaluation of steatosisclearlyare
required.
The most common stain used on both sides of the
Atlantic is H&E, although fat-specific stains are used
at
some centers in both countries. H&E identifies fatty
change by the presence of nonstaining vacuoles. Fatspecific stains, such as Oil red 0 and SudanIV, require
a positive color change. Several studies analyzed the
various merits of each technique and determined that
H&E can underestimate microsteatosis,whereas Oil
red 0 staining can generate false-positive results, especially afterUniversity of Wisconsin storage.*>5
From the
available information, it seems that a standard method
of staining and pathological assessmentneeds to be
introduced before meaningful worldwide comparisons
of clinical and experimental data can be made.
Several studies have shown that microvesicular steatosis in donor livers should not be considered a risk
factor for PNF. Urena etal5 found high-grade microvesicular steatosispresent in 31% of 72 donors, although
none showedfeaturesof
PNF after transplantation.
These livers resulted in significantly greater patient and
graft survival rates compared with a group with highgrade macrovesicular change.

The Use of F a q Liversfor Transplantation: A Survey

Fishbein et a l l 3 reviewed 426 transplantations and
identified 40 cases containingmoderate
to severe
microvesicular steatosis (>3O% steatosis). Donor obesity (42%) and traumatic death (68%) were the most
commonly associatedrisk factors. In this study, the
incidence of PNF and poorearly graftfunction inthese
livers was 5% and lo%, respectively. This was not significantly different from their results using normal livers. The investigators concluded
that
high-grade
microvesicularsteatosis
(>6O%) in adonororgan
should not be considered a contraindication to transplantation.
This has not been accepted by38% of UK and27%
of US respondents, who maintain that microvesicular
change is a risk factor for PNF, with alarge proportion
of surgeons (24% and 19%, respectively) admitting
that they remain unsure of therelationship. However,
the literature on this point suggests that use of livers
with microvesicular steatosis should no longer remain
controversial, andpure microvesicular change in a
donor biopsy specimen can be safelyignored.
In conclusion, we attempted to highlight some of
the controversialissues regarding the use of fatty livers
for transplantation and discuss how the existing literature might be applied to clinical practice. It is evident
from this survey that current opinions differ, not only
between the UK and theUS, but also among centersin
both countries. O n the whole,US respondents adopt a
more conservative approach, with greater emphasis on
histological assessmentthan their UK counterparts. It is
clear from this survey that more evidence from clinical
trials is needed so that some of these questions can be
answered and safe use of all viable livers achieved.
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